Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol’s Checkmate-331 Failure Not Likely To Endanger SCLC Labeling For Opdivo

Oct 12 2018

• By Joseph Haas

Digital illustration of lung cancer cells in color background

Related Content

Tecentriq's Small-Cell Lung Cancer Success Takes Edge Off Roche's IO Position

Sep 26 2018

Bristol's Opdivo Enjoys IO First-Mover Advantage In Small Cell Lung Cancer

Aug 17 2018

Related Companies

Bristol Myers Squibb Company

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Additional Topics

ImmunoOncology Clinical Trials Research & Development Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.